GQ1001 / GeneQuantum Healthcare  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GQ1001 / GeneQuantum Healthcare
ACTRN12620000592943: Phase I Dose Finding Study in Patients with HER2-Positive Advanced Solid Tumors

Recruiting
1
13
 
Conjugate Light (Australia) Pty Ltd, Conjugate Light (Australia) Pty Ltd
HER2-Positive Advanced Solid Tumors
 
 
NCT04450732 / ACTRN12620000592943: Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
96
US, RoW
GQ1001
GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd
HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
03/24
05/24

Download Options